Analyst Price Targets — RYTM
Latest News for RYTM
NVIDIA's blockbuster earnings sent shockwaves through tech on Thursday, but Wall Street analysts were busy reshaping the landscape elsewhere, issuing a flurry of upgrades, downgrades, and fresh initiations across energy, crypto infrastructure, banking, and biotech.
Bank of New York Mellon Corp acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 394,044 shares of the company's stock, valued at approximately $43,751,000. Bank of New York Mellon Corp owned
Duquesne Family Office has beefed up its healthcare holdings.
-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --
Rhythm Pharmaceuticals develops medicines for rare forms of obesity. The company has little competition in its target market.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RYTM.
U.S. House Trading
No House trades found for RYTM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.